Cancer Research Donn Young  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dyrskjøt, L.
Right arrow Articles by Ørntoft, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dyrskjøt, L.
Right arrow Articles by Ørntoft, T. F.
[Cancer Research 64, 4040-4048, June 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Gene Expression in the Urinary Bladder

A Common Carcinoma in Situ Gene Expression Signature Exists Disregarding Histopathological Classification

Lars Dyrskjøt1, Mogens Kruhøffer1, Thomas Thykjaer1, Niels Marcussen2, Jens L. Jensen3, Klaus Møller4 and Torben F. Ørntoft1

1 Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Aarhus N; 2 University Institute of Pathology, Aarhus University Hospital, Aarhus C; 3 Department of Theoretical Statistics, Department of Mathematical Sciences, Ny Munkegade, Aarhus C; and 4 Department of Urology, Aarhus University Hospital, Skejby, Aarhus N, Denmark

The presence of carcinoma in situ (CIS) lesions in the urinary bladder is associated with a high risk of disease progression to a muscle invasive stage. In this study, we used microarray expression profiling to examine the gene expression patterns in superficial transitional cell carcinoma (sTCC) with surrounding CIS (13 patients), without surrounding CIS lesions (15 patients), and in muscle invasive carcinomas (mTCC; 13 patients). Hierarchical cluster analysis separated the sTCC samples according to the presence or absence of CIS in the surrounding urothelium. We identified a few gene clusters that contained genes with similar expression levels in transitional cell carcinoma (TCC) with surrounding CIS and invasive TCC. However, no close relationship between TCC with adjacent CIS and invasive TCC was observed using hierarchical cluster analysis. Expression profiling of a series of biopsies from normal urothelium and urothelium with CIS lesions from the same urinary bladder revealed that the gene expression found in sTCC with surrounding CIS is found also in CIS biopsies as well as in histologically normal samples adjacent to the CIS lesions. Furthermore, we also identified similar gene expression changes in mTCC samples. We used a supervised learning approach to build a 16-gene molecular CIS classifier. The classifier was able to classify sTCC samples according to the presence or absence of surrounding CIS with a high accuracy. This study demonstrates that a CIS gene expression signature is present not only in CIS biopsies but also in sTCC, mTCC, and, remarkably, in histologically normal urothelium from bladders with CIS. Identification of this expression signature could provide guidance for the selection of therapy and follow-up regimen in patients with early stage bladder cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. W.F. Catto, S. Miah, H. C. Owen, H. Bryant, K. Myers, E. Dudziec, S. Larre, M. Milo, I. Rehman, D. J. Rosario, et al.
Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer
Cancer Res., November 1, 2009; 69(21): 8472 - 8481.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
C. Pollard, M. Nitz, A. Baras, P. Williams, C. Moskaluk, and D. Theodorescu
Genoproteomic Mining of Urothelial Cancer Suggests {gamma}-Glutamyl Hydrolase and Diazepam-Binding Inhibitor as Putative Urinary Markers of Outcome after Chemotherapy
Am. J. Pathol., November 1, 2009; 175(5): 1824 - 1830.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. S. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti Jr., H. Y. Chang, M. van de Rijn, et al.
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
PNAS, August 18, 2009; 106(33): 14016 - 14021.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein
Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma
J. Immunol., July 15, 2009; 183(2): 832 - 840.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. J. Cha, S. J. Noh, K. S. Kwon, C. Y. Kim, B.-H. Park, H. S. Park, H. Lee, M. J. Chung, M. J. Kang, D. G. Lee, et al.
Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma
Clin. Cancer Res., July 1, 2009; 15(13): 4453 - 4459.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Dyrskjot, M. S. Ostenfeld, J. B. Bramsen, A. N. Silahtaroglu, P. Lamy, R. Ramanathan, N. Fristrup, J. L. Jensen, C. L. Andersen, K. Zieger, et al.
Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro
Cancer Res., June 1, 2009; 69(11): 4851 - 4860.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. Lovat, A. Bitto, S.-Q. Xu, M. Fassan, S. Goldoni, D. Metalli, V. Wubah, P. McCue, G. Serrero, L. G. Gomella, et al.
Proepithelin is an autocrine growth factor for bladder cancer
Carcinogenesis, May 1, 2009; 30(5): 861 - 868.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Rosser, L. Liu, Y. Sun, P. Villicana, M. McCullers, S. Porvasnik, P. R. Young, A. S. Parker, and S. Goodison
Bladder Cancer-Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia
Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 444 - 453.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Yang, C. P. Dinney, Y. Ye, Y. Zhu, H. B. Grossman, and X. Wu
Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer
Cancer Res., April 1, 2008; 68(7): 2530 - 2537.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Xia, C. W. Lee, and D. C. Altieri
Tumor Cell Dependence on Ran-GTP-Directed Mitosis
Cancer Res., March 15, 2008; 68(6): 1826 - 1833.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Jin, X. Wang, J. Ying, A. H. Y. Wong, Y. Cui, G. Srivastava, Z.-Y. Shen, E.-M. Li, Q. Zhang, J. Jin, et al.
Epigenetic silencing of a Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers
PNAS, July 24, 2007; 104(30): 12353 - 12358.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. C. Smith, G. Oxford, A. S. Baras, C. Owens, D. Havaleshko, D. L. Brautigan, M. K. Safo, and D. Theodorescu
Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer
Clin. Cancer Res., July 1, 2007; 13(13): 3803 - 3813.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Dyrskjot, K. Zieger, F. X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P.-U. Malmstrom, M. de la Torre, et al.
Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study
Clin. Cancer Res., June 15, 2007; 13(12): 3545 - 3551.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. A. Knowles
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Carcinogenesis, March 1, 2006; 27(3): 361 - 373.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo
Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays
J. Clin. Oncol., February 10, 2006; 24(5): 778 - 789.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft
Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors
Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. J. Marsit, M. R. Karagas, A. Andrew, M. Liu, H. Danaee, A. R. Schned, H. H. Nelson, and K. T. Kelsey
Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer
Cancer Res., August 15, 2005; 65(16): 7081 - 7085.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann
Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder
Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis
Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas
Mol. Cell. Proteomics, April 1, 2005; 4(4): 570 - 581.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.